While we're waiting for news to drop, a few things to keep in mind:
1. The regulatory climate seems to be warming up to stem cell therapies.
2. The biotech media, and even mass media, seems to be covering stem cell news more and more.
3. BMSN has recently gotten its financials up-to-date. Most likely this is in preparation to attract financing and/or partners.
4. As someone noted here yesterday, according to Koos' Linked-In profile, he seems to be contacting investor/financial people.
5. The 30 days for the IND application are about up, and we haven't heard bad news yet. So most likely, we're approved.
6. Aplastic Anemia has already been granted Orphan Drug Status. So, once we're approved, the chance that BMSN applies for that and is awarded that status is likely.
7. BMSN is on the REG SHO List and short volume has been about 50% recently. So, we're wound up tight and shorts are gonna get squeezed hard if/when this thing takes off.
8. As has been mentioned here before, Koos has a lot of shares valued much higher than we're at and the scientists involved are going to be awarded shares based on milestone completion. In other words, their gain is our gain.
9. Finally, don't forget about the LOI for the breast cancer gene silencing therapy. The effort to attract investors/partners may be a step towards executing that goal.
All in all, things are looking really bright for BMSN this year! If you're not long, you're wrong...IMO
AI
